IngenioRx quarterly Drug and Biologic Pipeline Update available

The Q4 2020 IngenioRx Drug and Biologic Pipeline Update provides more insight into emerging biopharma therapies. The update provides our insight and analysis to help you understand how the drug and biologic pipeline could change in 2021. Highlights include:

• An examination of a novel therapy that may slow clinical decline in patients with Alzheimer’s disease
• In-depth reviews of proposed treatments for uterine fibroids and a rare metabolic disease in children
• An analysis of how and why specialty drugs are prominent in the pipeline
• Market trends likely affecting the pipeline and the state of gene therapies